Celltrion

Celltrion recently informed our shareholders and analysts that we have successfully secured deals with two of the top three Pharmacy Benefit Managers (or PBMs) to include 'Zymfentra', the world's first and only subcutaneous infliximab, in their formulary.

In addition, we are pleased to announce that on August 2 (EST), we successfully finalized a contract to list Zymfentra with the remaining one of the top three PBMs in the United States. As with the previous announcement, we ask for your understanding that we are unable to disclose the name of the PBM at this time due to contractual obligations.

The US insurance market is divided into commercial and public insurance, and the three major PBMs handle formulary listing contracts for both types of insurance separately. Celltrion has completed formulary listing agreements for both commercial and public insurance with two of the top three PBMs, including ESI. For the remaining PBM, we have closed a deal for public insurance, leaving only the commercial insurance contract to be finalized through further negotiations.

Within five months of its launch in March, Zymfentra has secured approximately 75% coverage across the entire U.S. insurance market. With this achievement, Celltrion has laid a strong foundation for the prescription growth of Zymfentra in the largest pharmaceutical market in the world. 

While Celltrion is dedicated to expanding Zymfentra’s listing coverage, our focus goes beyond PBM contract closures; we are committed to turning this achievement into tangible sales.

We extend our sincere gratitude for your unwavering support and confidence in Celltrion.